Status:

COMPLETED

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

Lead Sponsor:

Fresenius Kabi

Conditions:

Cachexia

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to ...

Eligibility Criteria

Inclusion

  • diagnosis of CHF or COPD
  • current body weight less than 6 months ago
  • BMI \>=20 and \<=30 kg/m2
  • CHF: LVEF \>=45% measured within the past 6 months
  • symptom status equivalent to NYHA class II to IV
  • biochemical abnormalities for total cholesterol, serum uric acid, abnormal high CRP
  • on standard therapy of CHF including ACE inhibitors and beta blockers
  • COPD: symptom status equivalent to GOLD standard class II to IV
  • FEV1 \< 80%
  • FEV1/FEV \< 70%

Exclusion

  • significant oedema in the time of screening and randomisation
  • concomitant inflammatory diseases
  • active infections including HIV and AIDS
  • liver failure
  • chronic renal failure (sCr\>1.5mg/dL) or cardiac pacemaker
  • acute or chronic infections
  • insulin treated diabetes mellitus
  • patient with established diagnosis of cachexia
  • life expectancy of less than 6 months in the opinion of the investigator
  • medications that impair sex hormone synthesis, secretion or function
  • patients with psychiatric diseases
  • body weight loss \> 5% during the last 6 months or \> 10% during the last 10 months
  • suspected allergy to any component of the investigational product(s)
  • fish oil supplementation within 3 months prior to the study entry
  • taking vitamin supplements in doses greater than the Recommended Daily Allowances

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2011

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00852020

Start Date

April 1 2009

End Date

April 1 2011

Last Update

January 31 2017

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Center of Cachexia Research, Department of Cardiology, Charité, Campus Virchow-Klinikum

Berlin, Germany, D-13353

2

Praxis für Pneumologie, Schwedt/Oder

Schwedt, Germany, D-16303

3

Regionalne Centrum Leczenia Chorób Płuc i Alergii, NZOZ ALLMED

Piekary Śląskie, Poland, PL-41-940

4

Specjalista Chorób Wewnętrznych Kardiolog

Ruda Śląska, Poland, PL-41-709